| Crystal Ollie, APN | |
|
104 Wall St, Poteau, OK 74953-4405 | |
| (918) 647-8630 | |
| (918) 635-3191 |
| Full Name | Crystal Ollie |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 7 Years |
| Location | 104 Wall St, Poteau, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396248381 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 93039 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Eastern Oklahoma Medical Center | Poteau, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Leflore County Hospital Authority | 7719916956 | 13 |
News Archive
In a post on the Global Network for Neglected Tropical Diseases' "End the Neglect" blog, Kerry Gallo of Children Without Worms writes, "Effective control strategies for several NTDs such as soil-transmitted helminthiasis (STH), trachoma, and schistosomiasis require that communities have access to water and latrines to break the cycle of infection," concluding, "The intertwined nature of water and sanitation issues and NTD control shows that our two sectors should work together in partnership to improve the health of communities and maximize impact".
Castrate-refractory prostate cancer, which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for the treatment of CRPC are lacking, and a number of factors must be considered when deciding between second-line hormonal therapy and chemotherapy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that two first-in-class agents — Merck's telcagepant and CoLucid's lasmiditan — will earn combined sales of approximately $1.3 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
Cancer risk was just one of the fears linked to the implants. Regulators have already called for them to be monitored closely following reports of high failure rates. Tiny metal ions made up of cobalt and chromium are thought to break off from the implants and leak into the blood, with fears that this leads to muscle and bone damage, and neurological issues.
› Verified 3 days ago
| Entity Name | Urgent Team Of Arkansas Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992041370 PECOS PAC ID: 1850539198 Enrollment ID: O20130529000209 |
News Archive
In a post on the Global Network for Neglected Tropical Diseases' "End the Neglect" blog, Kerry Gallo of Children Without Worms writes, "Effective control strategies for several NTDs such as soil-transmitted helminthiasis (STH), trachoma, and schistosomiasis require that communities have access to water and latrines to break the cycle of infection," concluding, "The intertwined nature of water and sanitation issues and NTD control shows that our two sectors should work together in partnership to improve the health of communities and maximize impact".
Castrate-refractory prostate cancer, which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for the treatment of CRPC are lacking, and a number of factors must be considered when deciding between second-line hormonal therapy and chemotherapy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that two first-in-class agents — Merck's telcagepant and CoLucid's lasmiditan — will earn combined sales of approximately $1.3 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
Cancer risk was just one of the fears linked to the implants. Regulators have already called for them to be monitored closely following reports of high failure rates. Tiny metal ions made up of cobalt and chromium are thought to break off from the implants and leak into the blood, with fears that this leads to muscle and bone damage, and neurological issues.
› Verified 3 days ago
| Entity Name | Belclin Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578021903 PECOS PAC ID: 6204177256 Enrollment ID: O20190401001907 |
News Archive
In a post on the Global Network for Neglected Tropical Diseases' "End the Neglect" blog, Kerry Gallo of Children Without Worms writes, "Effective control strategies for several NTDs such as soil-transmitted helminthiasis (STH), trachoma, and schistosomiasis require that communities have access to water and latrines to break the cycle of infection," concluding, "The intertwined nature of water and sanitation issues and NTD control shows that our two sectors should work together in partnership to improve the health of communities and maximize impact".
Castrate-refractory prostate cancer, which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for the treatment of CRPC are lacking, and a number of factors must be considered when deciding between second-line hormonal therapy and chemotherapy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that two first-in-class agents — Merck's telcagepant and CoLucid's lasmiditan — will earn combined sales of approximately $1.3 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
Cancer risk was just one of the fears linked to the implants. Regulators have already called for them to be monitored closely following reports of high failure rates. Tiny metal ions made up of cobalt and chromium are thought to break off from the implants and leak into the blood, with fears that this leads to muscle and bone damage, and neurological issues.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Crystal Ollie, APN 500 S Broadway St, Ste D, Poteau, OK 74953-3819 Ph: (918) 564-2270 | Crystal Ollie, APN 104 Wall St, Poteau, OK 74953-4405 Ph: (918) 647-8630 |
News Archive
In a post on the Global Network for Neglected Tropical Diseases' "End the Neglect" blog, Kerry Gallo of Children Without Worms writes, "Effective control strategies for several NTDs such as soil-transmitted helminthiasis (STH), trachoma, and schistosomiasis require that communities have access to water and latrines to break the cycle of infection," concluding, "The intertwined nature of water and sanitation issues and NTD control shows that our two sectors should work together in partnership to improve the health of communities and maximize impact".
Castrate-refractory prostate cancer, which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for the treatment of CRPC are lacking, and a number of factors must be considered when deciding between second-line hormonal therapy and chemotherapy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that two first-in-class agents — Merck's telcagepant and CoLucid's lasmiditan — will earn combined sales of approximately $1.3 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
Cancer risk was just one of the fears linked to the implants. Regulators have already called for them to be monitored closely following reports of high failure rates. Tiny metal ions made up of cobalt and chromium are thought to break off from the implants and leak into the blood, with fears that this leads to muscle and bone damage, and neurological issues.
› Verified 3 days ago
Lois L Gotes, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1013 Dewey Ave, Poteau, OK 74953 Phone: 918-647-2929 Fax: 918-647-2288 | |
Mr. Timothy Ray Olive, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2011 N Broadway St, Poteau, OK 74953 Phone: 918-647-7416 Fax: 918-647-3508 | |
Jeanne R Guinn, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 204 Wall St Ste A, Poteau, OK 74953 Phone: 918-647-2155 Fax: 918-967-4582 | |
Tracy Leann Morgan, APRN FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 210 W Robert St, Poteau, OK 74953 Phone: 918-649-0069 Fax: 918-649-0067 | |
Mrs. Kimberly Kay Cobb, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 210 W Robert St, Poteau, OK 74953 Phone: 918-649-0069 Fax: 918-649-0067 | |
Emily L Harrah, APRN-FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1120 Tarby Rd, Poteau, OK 74953 Phone: 918-647-2155 Fax: 918-647-4095 | |
Mrs. Jami D Herring, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 204 Wall St Ste A, Poteau, OK 74953 Phone: 918-647-2155 |